FDA
-
-
-
-
-
-
-
Acadia Pharmaceuticals Announces DAYBUE® STIX (trofinetide) is Now Broadly Available in the United States for the Treatment of Rett Syndrome
-
-
-
-
-
-
-
Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Operating Overview
-
-
-
-
-
-
-
Acadia Pharmaceuticals Provides Business and Pipeline Updates at 44th Annual J.P. Morgan Healthcare Conference
-
-
-
-
-
-
-
Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences
-
-
-
-
-
-
-
Real World Data from LOTUS Study Evaluating Long-term Efficacy and Tolerability Outcomes of DAYBUE® (trofinetide) in Patients with Rett Syndrome Published in Developmental Medicine and Child Neurolog
-
-
-
-
-
-
-
Acadia Pharmaceuticals Reports Second Quarter 2025 Financial Results and Operating Overview
-
-
-
-
-
-
-
Acadia Pharmaceuticals Hosts Inaugural R&D Day Showcasing Pipeline and Long-Term Value Drivers
-
322,948 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

